What question did this study set out to answer?

This review aims to explore the mechanisms by which GLP-1 receptor agonists may provide neuroprotection in various neurological disorders.

June 13, 2026Open Access

GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation

Puntos clave

This review aims to explore the mechanisms by which GLP-1 receptor agonists may provide neuroprotection in various neurological disorders.
Review of preclinical evidence in animal models of neurological disorders including Alzheimer’s and Parkinson’s diseases.
Discussion of the main molecular pathways activated by GLP-1 receptor agonists, such as cAMP/PKA/CREB and PI3K/Akt.
Evaluation of clinical trial data regarding cognitive and motor function improvements in patients.
Preclinical studies show GLP-1 receptor agonists lead to reduced protein aggregation and neuron loss in multiple neurological models.
Clinical trials report mixed outcomes, with some showing modest cognitive improvements and others no meaningful effects on disease progression.
Variation in blood-brain barrier penetration among different GLP-1 receptor agonists may explain inconsistencies in clinical trial results.

Resumen

Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity. More recently, it has become clear that these receptors are widely distributed throughout the central nervous system (CNS), which has raised the possibility of repurposing these drugs for neurological disorders. In this review we go through the evidence across a range of neurological conditions, discuss the main mechanisms thought to explain their neuroprotective effects, and point out the hurdles that still need to be cleared before they can be used in the clinic. Preclinical work has been fairly consistent. These drugs activate the cAMP/PKA/CREB pathway to boost BDNF expression. They also turn on the PI3K/Akt pathway, which reins in GSK-3β and cuts down tau hyperphosphorylation. At the same time, they put the brakes on NLRP3 inflammasome activation in microglia and get AMPK dependent mitochondrial biogenesis and autophagy going. In animal models of Alzheimer’s disease (AD), Parkinson’s disease (PD), ischemic stroke, intracerebral hemorrhage (ICH), Huntington’s disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), depression, epilepsy, and spinal cord injury (SCI), these cellular changes add up to less protein aggregation, less neuron loss, and better functional outcomes. Clinical data are harder to interpret. Some trials have shown modest improvements in cognition or motor function, but others have found no meaningful effect on disease progression. One thing that does not get enough attention is that different GLP-1 receptor agonists cross the blood–brain barrier at widely varying rates, and these differences could well explain why trial results have been so mixed. Looking ahead, getting these drugs into the clinic will depend on choosing the ones that actually reach the CNS, developing biomarkers that can predict who will respond, and designing trials that take disease heterogeneity into account. Seen this way, this review offers a practical framework for turning mechanistic insights into real patient benefit. Keywords: GLP-1 receptor agonists, neuroprotection, neuroinflammation, Alzheimer’s disease, Parkinson’s disease

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo